MGMT and neoplasm: In a correlative specimen analysis from EORTC 26981/NCIC CE.3, Hegi et al. found that those with a methylated MGMT promoter had markedly increased survival after receiving TMZ compared to those with unmethylated MGMT promoters, suggesting that stratification of individuals based on tumor MGMT methylation status may be a necessary part of future trials and treatment regimens [24,25].